Oncolytics Biotech Inc.

447 articles with Oncolytics Biotech Inc.

• 

  Top 6 Biotech Stocks of 2017

  12/20/2017

  When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates.

• Acerus Appoints Mr. Mark Lievonen to Its Board of Directors

  12/7/2017

  The appointment fills the vacancy resulting from Mr. Tom Rossi’s resignation from the Board of Directors.

• Oncolytics Biotech Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN in Metastatic Breast Cancer

  12/5/2017

  The Letter refers to the proposed use of pelareorep in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative metastatic breast cancer patients in a pivotal phase 3 registration study.

• Oncolytics Biotech Establishes Scientific Advisory Board Focused on REOLYSIN Registration Study in Metastatic Breast Cancer

  11/30/2017

  The SAB will provide Oncolytics with significant clinical expertise and experience in breast cancer drug development in both the U.S. and Europe.

• 

  Oncolytics Biotech, Adlai Nortye Forge $86.6M Reolysin Deal

  11/17/2017

  Under the terms of The Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan.

• Oncolytics Biotech Announces 2017 Third Quarter Results

  11/8/2017

  Oncolytics Biotech today announced its financial results and operational highlights for the quarter ended September 30, 2017.

• Oncolytics Biotech Appoints Deborah Brown to Board of Directors

  11/2/2017

  "Ms. Brown's wealth of experience in new product launches and market expansion will lend valuable insights as we progress REOLYSIN toward commercialization," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech.

• Oncolytics Biotech Announces Successful End-Of-Phase II Meeting With FDA For REOLYSIN In Metastatic Breast Cancer

  9/18/2017

• Oncolytics Biotech Announces First Patient Treated In MUK Eleven Study

  9/14/2017

• Oncolytics Biotech Announces The Presentation Of REOLYSIN Clinical Data At ESMO 2017 Congress

  9/11/2017

• Oncolytics Biotech Announces 2017 Second Quarter Results

  8/3/2017

• Oncolytics Biotech To Present REOLYSIN Safety Data In Combination With Chemotherapy At ESMO 2017 Congress

  7/26/2017

• Oncolytics Biotech Appoints Andrew De Guttadauro, President Of Oncolytics Biotech (U.S.) Inc.

  6/29/2017

• Oncolytics Biotech Opens U.S. Based Office In San Diego

  6/27/2017

• Oncolytics Biotech Announces Closing Of Public Offering Of Units

  6/1/2017

• Oncolytics Biotech Prices Public Offering Of Units

  5/24/2017

• Oncolytics Biotech Announces Proposed Public Offering

  5/24/2017

• Oncolytics Biotech Announces Participation In World Immunotherapy Congress USA 2017

  5/23/2017

• Oncolytics Biotech Announces FDA Fast Track Designation For REOLYSIN In Metastatic Breast Cancer

  5/8/2017

• Oncolytics Biotech Announces Voting Results From Its Annual Meeting Of Shareholders

  5/5/2017